Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation […]
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update
Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Results from […]
MediWound Reports Third Quarter 2018 Financial Results
Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid® for sulfur mustard injuries Conference call […]
VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the […]
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to […]
U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome
Intended for U.S. Audience U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for […]
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., and BEIJING, China, Nov. 13, 2018 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical […]
Cerecor Reports Third Quarter 2018 Results
BALTIMORE, Nov. 13, 2018 (GLOBE NEWSWIRE) — Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company […]
Valeritas Signs Exclusive Middle East Distribution Agreement with Julphar
– V-Go distribution deals now span 14 countries and territories – BRIDGEWATER, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) — Valeritas […]
Albireo Reports Third Quarter 2018 Financial Results
Odevixibat selected as International Nonproprietary Name (INN) for A4250 A4250 granted Fast Track and additional Orphan Drug designations A4250 Phase […]
